埃森哲：重塑相关性：COVID-19疫情下与医疗保险提供者进行药物互动新模型-埃森哲（英文版）（30页）.pdf

1、NOWNEXTCOVID-19: What to do Now, What to do Next Accenture Healthcare Provider Survey May 2020 Reinventing Relevance New Models for Pharma Engagement with Healthcare Providers in a COVID-19 World 2 With this survey, we sought to understand how healthcare provider operations and needs have changed du

2、ring COVID-19, and which of these changes will have long-lasting implications for how healthcare providers interact with their patients and with pharma companies. About the Accenture COVID-19 Healthcare Provider Survey Participants The survey participants identified themselves as one of the followin

3、g healthcare disciplines: 25%25%25%25% General Practitioner OncologistImmunologist Cardiologist Countries N = 720 120 participants from each country: USA, UK, France, Germany, China & Japan. The survey data was collected in May-June 2020, during a time of COVID-19 restrictions in all 6 countries. 3

4、About the Audience Profile Healthcare settingTotal number of patients treated each year Mean: 1,717 patients 901-10001,000+ 501-600 601-700 401-500 301-400 701-800 801-900 21% 18% 14% 12% 12% 9% 7% 7% Practice setting Independent Hospital Private/Independent Hospital setting Hospital Network/ IDN/AC

5、O NHS Hospital (UK) Private health institute (France) Resident doctor (Germany) Physicians Group/ Private Practice Base: Total respondents (720) 4 About the Audience Profile Size of practice Location of practice 8% 23% 23% 23% 14% 8% Between 2 and 5 professional practitioners Between 6 and 10 profes

6、sional practitioners Between 11 and 20 professional practitioners Between 21 and 30 professional practitioners Over 30 professional practitioners Single person specialist Base: Total respondents (720) 57% 36% 6% 1% Metropolitan (major city) Medium sized city Small townVillage/Rural 5 COVID-19 has sh